Charu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH, is a physician leader in Airways Malignancies Research, director of Precision Oncology Innovation at Penn Center for Cancer Care Innovation, section chief of Head & Neck and Thoracic Cancers, Hematology-Oncology, and the Leslye M. Heisler Professor for Lung Cancer Excellence at Penn Medicine in Philadelphia, Pennsylvania.

Articles

Propylactic Strategies in Managing Dermatologic AEs with Amivantamab: Expert Insights from the COCOON Trial

July 15th 2025

Panelists discuss that the Cocoon trial’s four-part prophylactic regimen—including oral antibiotics, clindamycin topical treatment, nail toxicity prevention, and ceramide-based lotions—significantly reduces skin toxicities like scalp rashes in EGFR inhibitor therapies, emphasizing the importance of patient and provider education to ensure adherence and improve treatment tolerability.

Mitigating Potential IRRs with Amivantamab: Clinical Insights from the SKIPPirr

July 15th 2025

Panelists discuss that the skipper regimen—a prophylactic dexamethasone schedule started days before infusion—has significantly reduced infusion-related reactions from about 66% to 22%, improving patient comfort and clinic workflow while emphasizing ongoing education and early management to ensure safety.

Adverse Event Management Strategies for FLAURA2 and MARIPOSA: Expert Insights and Best Practices

July 8th 2025

Panelists discuss that chemotherapy plus osimertinib requires managing early hematologic toxicities and EGFR-related rash and diarrhea with close monitoring, while the bispecific antibody regimen involves proactive prevention of infusion reactions, anticoagulation for VTE risk, and intensive rash management to support treatment adherence and patient quality of life.

FLAURA2 and MARIPOSA: Expert Insights on Safety Outcomes

July 8th 2025

Panelists discuss the evolving safety profiles of first-line EGFR-mutated lung cancer treatments, highlighting that chemotherapy combinations cause expected hematologic toxicities and fatigue, while bispecific antibody regimens bring unique challenges such as infusion reactions, more severe rashes and diarrhea, peripheral edema, and a notably increased risk of venous thromboembolism that warrants prophylactic anticoagulation and careful patient monitoring.

Monitoring Therapies in Patients with CNS Involvement

July 1st 2025

Panelists discuss the critical role of regular brain MRI monitoring in EGFR-mutant lung cancer, balancing timely detection of intracranial progression with the risks of early radiation; they emphasize individualized treatment sequencing guided by progression patterns and resistance profiling through biopsies and liquid biopsies to optimize patient outcomes.

CNS Data from FLAURA2 and MARIPOSA

July 1st 2025

Panelists discuss the evolving management of CNS metastases in EGFR-mutant lung cancer, highlighting how third-generation TKIs and combination regimens from the FLORA and Mariposa trials delay CNS progression and reduce new brain metastases, supporting a shift away from upfront radiation in asymptomatic patients.

FLAURA2 and MARIPOSA: Factors for Consideration when Choosing Optimal Therapy

June 24th 2025

Panelists discuss how the availability of three frontline options for EGFR-mutant NSCLC has complicated treatment selection, prompting highly individualized, hour-long consultations that balance disease biology, patient values, and the trade-offs between monotherapy and combination regimens.

MARIPOSA: Clinical Implications of Updated Key Data

June 24th 2025

Panelists discuss the Mariposa trial’s landmark overall survival benefit with amivantamab plus lazertinib over osimertinib monotherapy in EGFR-mutant NSCLC, marking a paradigm shift toward durable survival and reinforcing the value of optimized patient selection and adherence to combination regimens.

FLAURA2 Updated Key Outcomes and it's Clinical Impact

June 17th 2025

Panelists discuss how the FLAURA2 trial has reshaped EGFR-mutant NSCLC treatment by demonstrating meaningful progression-free survival gains with osimertinib plus chemotherapy, while emphasizing the importance of protocol adherence, long-term outcome potential, and the ongoing pursuit of curative strategies.

EGFR-mutated NSCLC: Evolving Treatment Landscape

June 17th 2025

Panelists discuss evolving first-line strategies for EGFR-mutant NSCLC, highlighting the expanding role of combination regimens, CNS efficacy, and the need for personalized treatment selection and toxicity management, especially in younger, well-informed patients.

Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Pooled Data for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Addressing CNS Involvement in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Selecting a TKI in ROS1+ NSCLC Management

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Treatment Sequencing Decisions in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

The Prevalence of ROS1 Fusions in Advanced NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

Dr Aggarwal on Data for CAN-2409 Plus Valacyclovir and Continued ICIs in NSCLC

September 25th 2024

Charu Aggarwal, MD, MPH, FASCO, on data for CAN-2409 plus valacyclovir with continued immune checkpoint inhibitors in advanced non–small cell lung cancer.

Dr Aggarwal on the Rationale For Evaluating CAN-2409 in NSCLC

August 12th 2024

Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.

Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05

June 27th 2024

Tropion-Lung05 (NCT04484142) is a phase 2, multicenter, single-arm, open-label study evaluating Dato-DXd in patients with advanced/metastatic NSCLC with actionable genomic alterations who have progressed on or after targeted therapy and platinum-based CT.